Xilio Therapeutics, Inc. (XLO): Price and Financial Metrics

Xilio Therapeutics, Inc. (XLO): $3.24

0.18 (+5.88%)

POWR Rating

Component Grades













Add XLO to Watchlist
Sign Up

Industry: Biotech



in industry

XLO Stock Price Chart Interactive Chart >

Price chart for XLO

XLO Price/Volume Stats

Current price $3.24 52-week high $27.95
Prev. close $3.06 52-week low $2.30
Day low $3.04 Volume 83,500
Day high $3.50 Avg. volume 38,944
50-day MA $5.04 Dividend yield N/A
200-day MA $0.00 Market Cap 89.01M

Xilio Therapeutics, Inc. (XLO) Company Bio

Xilio Therapeutics, Inc., a biotechnology company, designs immunotherapies to improve the immune system for cancer patients. Its checkpoint inhibitor programs include XTX101, is a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1 clinical trials in patients with solid tumors; and cytokine programs comprise XTX202, XTX301, and XTX401, which are modified form of IL-2 that is masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

XLO Latest News Stream

Event/Time News Detail
Loading, please wait...

XLO Latest Social Stream

Loading social stream, please wait...

View Full XLO Social Stream

Latest XLO News From Around the Web

Below are the latest news stories about Xilio Therapeutics Inc that investors may wish to consider to help them evaluate XLO as an investment opportunity.

RiverVest Venture Management LLC Buys Xilio Therapeutics Inc

Investment company RiverVest Venture Management LLC (Current Portfolio) buys Xilio Therapeutics Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, RiverVest Venture Management LLC.

Yahoo | February 7, 2022

Xilio Therapeutics to Participate in the Guggenheim 4th Annual Oncology Day

WALTHAM, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm. D., president and chief executive officer, and Marty Huber, M.D., president of research and development and chief medical officer of Xilio Therapeutics, will participate in a virtual fireside chat during the Guggenheim 4th Annual Oncology Day on Thursday, Februa

Yahoo | February 3, 2022

Are Institutions Heavily Invested In Xilio Therapeutics, Inc.'s (NASDAQ:XLO) Shares?

The big shareholder groups in Xilio Therapeutics, Inc. ( NASDAQ:XLO ) have power over the company. Institutions will...

Yahoo | January 25, 2022

H.C. Wainwright Reaffirms Their Buy Rating on Xilio Therapeutics (XLO)

H.C. Wainwright analyst Michael King reiterated a Buy rating on Xilio Therapeutics (XLO – Research Report) today and set a price target of $36.00. The company's shares closed last Thursday at $13.62. According to TipRanks.com, King is a 4-star analyst with an average return of 13.4% and a 42.8% success rate. King covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Intellia Therapeutics, and Werewolf Therapeutics. Currently, the analyst consensus on Xilio Therapeutics is a Strong Buy with an average price target of $34.75.

Catie Powers on TipRanks | January 20, 2022

Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX202 for the Treatment of Patients with Solid Tumors

WALTHAM, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that the first patient has been dosed in the company’s Phase 1/2 clinical trial evaluating XTX202 for the treatment of solid tumors. XTX202 is a modified form of IL-2 that is designed to localize activity in the tumor microenvironment (TME), with the goal of overcoming the known tolera

Yahoo | January 20, 2022

Read More 'XLO' Stories Here

XLO Price Returns

1-mo -8.22%
3-mo -72.50%
6-mo -79.55%
1-year N/A
3-year N/A
5-year N/A
YTD -79.75%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.411 seconds.